Investment research report for DVA

Table of Contents

Executive Summary
Valuation Analysis
Industry and Competitors Analysis
Financial Analysis
Earnings Call Multi-Year Analysis
Financial Statements Multi Year
Insider Trading Analysis
Management Compensation Benchmark Analysis
Proxy Statement Analysis
News Analysis
Technical Indicators Analysis
Financial Statements Annual
Financial Statements Quarterly
Earnings Call Analysis

Executive Summary

Company Description

DaVita Inc. is a leading provider of kidney dialysis services in the United States and internationally. The company operates a network of outpatient dialysis centers and provides related services, including integrated kidney care, clinical research, and laboratory services. DaVita is focused on delivering high-quality patient care and driving innovation in the field of kidney disease treatment.

Financial Performance

DaVita has demonstrated consistent revenue growth and profitability in recent years, driven by its core dialysis business and strategic initiatives. The company’s financial position remains strong, with ample liquidity and cash flow generation. However, DaVita faces ongoing cost pressures, particularly related to labor and operating expenses, which have impacted margins in certain periods.

Strategic Initiatives

A key strategic focus for DaVita is the expansion of its Integrated Kidney Care (IKC) business, which represents a shift towards value-based kidney care. While currently operating at a loss, the company sees significant long-term potential in this segment. DaVita is also pursuing international growth through acquisitions and partnerships, as well as investing in clinical research and innovation.

Competitive Landscape

DaVita operates in a competitive landscape, with its primary competitor being Fresenius Medical Care, a subsidiary of the larger Fresenius SE & Co. KGaA. DaVita’s competitive advantages include its scale, vertically integrated business model, and focus on clinical quality and patient outcomes. However, the company faces regulatory challenges and potential reimbursement pressures that could impact its profitability.

Back to Table of Contents

Valuation Analysis

PE ratio

  • Low: 9.4630093702545
  • Base: 14.218897429539998
  • High: 18.974785488825496

PB ratio

  • Low: 1.1931537637802032
  • Base: 7.276900879317658
  • High: 13.360647994855114

EPS Growth

  • Low: 2.02%
  • Med: 7.43%
  • High: 11.12%

FCF Growth

  • Low: 5.05%
  • Med: 14.82%
  • High: 20.26%

Value forecast by FCF

  • Low: 319.69
  • Med: 576.09
  • High: 806.55

Value forecast by EPS

  • Low: 268.67
  • Med: 367.78
  • High: 459.53

The current price for DVA is $142.21.

Price target for 18 months from now

  • Low: 166.28
  • Med: 196.88
  • High: 224.51

Price target for 4 years from now

  • Low: 206.40
  • Med: 287.99
  • High: 361.68

Price target for 10 years from now

  • Low: 302.68
  • Med: 506.66
  • High: 690.88

The net present value multiplier discounted at 10.22% indicates the value of the stock is:
– Low: 2.13
– Med: 3.56
– High: 4.86

The upside/downside ratio is 9.86, and our rating is Strong Buy.

Back to Table of Contents

Industry and Competitors Analysis

Dialysis Services Market

Based on the information provided, DVA (DaVita Inc.) operates in the medical care facilities industry, providing kidney dialysis services and related products and services. Its main competitors appear to be:

  1. Fresenius SE & Co. KGaA (FSNUY) – A large international healthcare company with a significant presence in dialysis services through its Fresenius Medical Care segment.

  2. Surgery Partners, Inc. (SGRY) – Operates a network of surgical facilities, including ambulatory surgery centers and surgical hospitals.

  3. Acadia Healthcare Company, Inc. (ACHC) – Provides behavioral healthcare services through a network of inpatient psychiatric hospitals, residential treatment centers, and outpatient clinics.

  4. The Ensign Group, Inc. (ENSG) – Operates skilled nursing and senior living facilities, as well as providing other ancillary services.

  5. Tenet Healthcare Corporation (THC) – A diversified healthcare services company operating general acute care hospitals, ambulatory surgery centers, and other healthcare facilities.

  6. HCA Healthcare, Inc. (HCA) – One of the largest operators of general acute care hospitals and other healthcare facilities in the United States.

In terms of competitive positioning, DVA appears to be a major player in the dialysis services market, with a significant network of outpatient dialysis centers and related services. However, it faces competition from the dialysis services segment of Fresenius Medical Care, which is a part of a larger healthcare conglomerate. DVA’s focus on kidney care services and its scale in this area could be considered its competitive advantage.

Back to Table of Contents

Chart of Competitors

"Chart of Competitors"

Back to Table of Contents

Financial Analysis

Financial Strength

The company has a relatively high debt-to-equity ratio (around 8-16 in recent years), indicating a higher reliance on debt financing. However, the interest coverage ratio (around 3-6) suggests the company can service its debt obligations. The current ratio is generally above 1, indicating the company has enough current assets to cover current liabilities. Return on equity and return on assets have been volatile but mostly positive in recent years, suggesting decent profitability.

Potential for Growth

Revenue growth has been relatively flat or slightly positive in recent years, with some fluctuations. The company operates in the healthcare industry, specifically kidney dialysis services, which could provide growth opportunities due to an aging population and increasing prevalence of chronic kidney diseases. The company has been expanding its international presence, which could drive future growth.

Competitive Advantage

DaVita is one of the largest providers of kidney dialysis services in the United States, giving it a significant market presence and economies of scale. The company’s vertically integrated business model, including owning dialysis centers, laboratories, and providing related services, could provide a competitive advantage.

Quality of Management

The financial metrics suggest that management has been able to maintain profitability and manage debt levels, although there have been some fluctuations. The company’s expansion into international markets and diversification into related services could be seen as strategic moves by management to drive growth.

Shareholder Friendliness

The company does not pay dividends, which may be less attractive to income-seeking investors. Share buybacks or other shareholder-friendly initiatives are not evident from the provided data.


The price-to-earnings (P/E) ratio has varied significantly, ranging from around 8 to 18 in recent years, suggesting potential over- or undervaluation at different times. The price-to-book (P/B) ratio has generally been above 1, indicating that the market values the company higher than its book value. Analyst estimates for future revenue, EBITDA, and earnings suggest potential for growth, which could impact the company’s valuation going forward.

Overall, DaVita appears to have a relatively strong financial position and competitive advantage in its industry, with potential for growth driven by industry trends and international expansion. However, its high debt levels, lack of dividends, and fluctuating valuation metrics suggest potential risks and areas for improvement in terms of shareholder friendliness and consistent growth.

Back to Table of Contents

Chart of Key Per Share Metrics

"Chart of Key Per Share Metrics"

Back to Table of Contents

Chart of Absolute Metrics

"Chart of Absolute Metrics"

Back to Table of Contents

Earnings Call Multi-Year Analysis

Strategic Focus on Integrated Kidney Care (IKC)

DaVita is making a significant strategic shift towards value-based kidney care through its IKC business. While currently operating at a loss, the company sees IKC as a major long-term growth opportunity and is investing heavily in scaling up this business. Investors should closely monitor the progress and financial performance of IKC.

Core Dialysis Business Resilience

Despite challenges from COVID-19, labor shortages, and cost pressures, DaVita’s core dialysis business has remained relatively resilient, with solid financial performance and a focus on operational improvements. The company expects to return to pre-pandemic treatment growth levels.

COVID-19 Impact and Recovery

The COVID-19 pandemic has had a significant impact on DaVita, including excess patient mortality, treatment volume declines, and higher costs. While the company expects a gradual recovery, the timing and magnitude of the rebound remain uncertain, and future COVID-19 surges could pose additional risks.

Labor and Cost Pressures

DaVita has faced significant labor shortages and cost pressures, particularly related to wage increases and contract labor. The company is implementing various cost-saving initiatives to offset these pressures, but they are expected to persist in the near term.

Long-Term Growth Outlook

Despite near-term challenges, DaVita maintains a positive long-term outlook, with expectations for low-to-mid single-digit compound annual growth rates (CAGRs) in operating income and adjusted EPS over a multi-year horizon, driven by the core dialysis business and the potential of IKC.

Capital Allocation

DaVita has shifted its capital allocation priorities towards debt reduction and maintaining its target leverage ratio, while moderating share repurchases in the near term.

Regulatory and Reimbursement Dynamics

DaVita continues to navigate regulatory challenges, such as the potential impact of the Marietta Memorial Hospital ruling and advocating for appropriate reimbursement rates from government and commercial payers.

Overall, long-term investors should focus on DaVita’s ability to manage near-term challenges, execute its strategic shift towards value-based kidney care through IKC, and deliver on its long-term growth expectations while maintaining a disciplined approach to capital allocation and cost management.

Back to Table of Contents

Financial Statements Multi Year

Revenue and Earnings Growth

The company demonstrated steady revenue growth year-over-year, with a 6.9% increase in Q1 2024 compared to Q1 2023. Operating income also grew significantly, increasing 55.1% in Q1 2024 vs Q1 2023. For full year 2023, revenue increased 3.5% and operating income grew 12% compared to 2022, driven by the core U.S. dialysis business.

Segment Performance

The U.S. dialysis segment is the primary driver of profitability, generating operating margins over $1.7 billion in 2023. Growth was supported by higher revenue per treatment. The ancillary services segments like integrated kidney care showed mixed performance but contributed modest profit growth.

Cash Flows and Liquidity

Operating cash flows remained strong, increasing 28.9% year-to-date in 2023 vs 2022. Free cash flow also grew 31.9% over the same period. The company maintains ample liquidity with over $1 billion in cash/revolving credit available as of Q1 2024 after refinancing debt.

Cost Management and Margins

While revenues grew, the company faced inflationary cost pressures from higher compensation, travel, and operating expenses that impacted margins, especially in 2022. Ongoing cost savings initiatives like third-party providers and clinic optimization helped mitigate some of these headwinds.

Strategic Initiatives

The company continues pursuing strategic acquisitions, spending over $120 million on dialysis/ancillary businesses in 2022-2023. Share repurchases also remained a use of cash, with $1.55 billion in buybacks in 2021.


The company faces some regulatory investigations and legal proceedings that present potential risks to monitor long-term.

Overall, the financial statements depict a company with a strong market position in its core dialysis business that is delivering revenue, earnings, and cash flow growth. Maintaining cost discipline, executing strategic acquisitions, and managing the regulatory landscape will be important for sustaining long-term performance.

Back to Table of Contents

Insider Trading Analysis

Long-Term Patterns

The CEO (STAFFIERI MICHAEL DAVID) and CFO (ACKERMAN JOEL) have consistently received large awards of stock and stock appreciation rights over the years, indicating they are heavily incentivized through equity compensation. Several other key executives like the Chief Accounting Officer (HEARTY JAMES O) and Chief Operating Officer (Waters Kathleen Alyce) have also received substantial equity awards. Insider selling has been relatively limited, with most transactions involving stock awards, option exercises, and share withholding for tax purposes.

Recent Patterns

In 2024, there were a large number of stock awards granted to various executives and directors, with the shares vesting at $0 cost. The CEO (STAFFIERI MICHAEL DAVID) and CFO (ACKERMAN JOEL) received the largest awards, with STAFFIERI getting over 100,000 shares and ACKERMAN getting over 180,000 shares. The CEO and CFO also engaged in some share sales and option exercises, but the net effect was an increase in their ownership levels. Other key executives like the Chief Operating Officer (Waters Kathleen Alyce) and Chief Accounting Officer (HEARTY JAMES O) also received significant equity awards.


The heavy use of equity compensation, especially for the CEO and CFO, suggests the company is closely aligning the interests of top management with shareholders. The lack of substantial insider selling indicates executives remain confident in the long-term prospects of the company. The recent large equity awards to key executives could signal the company’s belief in its future growth potential and a desire to retain and incentivize its leadership team.

Overall, the insider trading patterns suggest DaVita’s management team is heavily invested in the company’s success and is being compensated in a way that should incentivize long-term value creation for shareholders.

Back to Table of Contents

Management Compensation Benchmark Analysis

Base Salary Portion of Total Compensation

The base salary portion of total compensation for DVA’s executives is relatively low, averaging around 21.14% across all years and executives reported. This suggests that a significant portion of their total compensation is tied to variable pay components like bonuses and incentive plan compensation.

Comparison to Peers

Compared to other healthcare companies like Surgery Partners (SGRY), Acadia Healthcare (ACHC), Tenet Healthcare (THC), and HCA Healthcare (HCA), DVA’s executives have a lower base salary percentage of their total compensation. The average base salary percentage for the other companies ranges from around 22-32%, higher than DVA’s average.

Alignment with Shareholder Interests

This compensation structure, with a lower base salary and higher variable pay, may help align the interests of DVA’s executives with creating long-term shareholder value, as a larger portion of their compensation is tied to the company’s performance.

Lack of Bonus Payouts

However, the lack of bonus payouts in recent years for some DVA executives, such as the CEO and CFO, could be a concern for investors looking for strong pay-for-performance alignment.

Overall Assessment

Overall, the executive compensation structure at DVA appears to be more heavily weighted towards variable, performance-based pay compared to fixed base salaries, which is generally considered a positive for aligning executive incentives with long-term shareholder interests. But the lack of bonus payouts in recent years is something a long-term investor may want to monitor.

Back to Table of Contents

Proxy Statement Analysis

Alignment of Executive Compensation with Long-Term Shareholder Value

The following analysis is based on the latest proxy statement of DVA:

Based on the information provided in the proxy statement, here are the key insights for a long-term investor regarding the alignment of executive compensation with creating long-term shareholder value:

  1. Significant portion of compensation is in the form of long-term incentives like performance-based restricted stock units (PSUs) and stock options, which vest over multi-year periods (typically 3 years or more). This encourages executives to focus on sustained long-term performance.

  2. The long-term incentive payouts are tied to specific performance metrics such as total shareholder return (TSR), earnings per share (EPS), and other key strategic measures aligned with long-term value creation.

  3. The company has established stock ownership guidelines, requiring executives to maintain a significant equity stake in the company, further aligning their interests with shareholders.

  4. Clawback policies are in place, allowing the company to recoup incentive compensation in cases of financial restatements or misconduct, reinforcing the focus on ethical and sustainable long-term performance.

  5. The overall structure of the compensation program, with its emphasis on long-term incentives, multi-year vesting periods, and performance metrics tied to shareholder value creation, appears designed to align executive incentives with the interests of long-term investors.

While a detailed assessment would require a thorough review of the specific plan designs and performance targets, the key elements outlined in the proxy statement suggest a reasonable alignment between executive compensation and the creation of long-term shareholder value.

Back to Table of Contents

News Analysis for DaVita Inc

Positive Sentiment

DaVita has been frequently recommended as a good value stock to buy by analysts, citing its attractive valuation, strong cash flows, and potential for share buybacks. The company has been beating earnings estimates in recent quarters and raising its full-year earnings guidance, indicating solid financial performance. DaVita is seen benefiting from favorable industry trends like the growing need for dialysis services due to rising kidney disease prevalence. The stock is often featured in lists of top holdings or picks from reputed value investors like Warren Buffett’s Berkshire Hathaway.

Potential Concerns

DaVita faces legal challenges like an antitrust lawsuit related to alleged “no-poaching” agreements with rivals. The company has a high debt load, which increases interest expenses and financial risk, especially in a rising rate environment. Regulatory changes or pricing pressures in the dialysis market could impact DaVita’s profitability and cash flows. The COVID-19 pandemic disrupted some of DaVita’s operations and patient volumes, though the impact appears temporary.

Overall, the sentiment seems cautiously optimistic, with analysts highlighting DaVita’s attractive valuation and cash flow generation capabilities. However, legal risks, debt levels, and industry headwinds are factors to watch closely for long-term investors. Thorough due diligence on the company’s fundamentals and risk factors is advisable.

Back to Table of Contents

Technical Indicators Analysis

Next Week Trading

The TEMA (Triple Exponential Moving Average) is showing a slightly bullish trend, indicating potential upward momentum in the short-term. The RSI (Relative Strength Index) is around 54, suggesting the stock is in a neutral territory and not overbought or oversold, indicating potential for trading opportunities in the near future. The recent price action has been relatively volatile, with the stock trading within a range, providing potential trading opportunities for short-term investors.

Resistance and Support Levels

The 20-day SMA (Simple Moving Average) and 50-day SMA are currently acting as support levels, while the 200-day SMA is providing a long-term support level. The stock has faced resistance around the $145 level, which could be a key level to watch going forward.

Short-Term Investor

The recent price action and technical indicators suggest potential trading opportunities in the short-term, with the stock trading within a range and the TEMA and RSI indicating a neutral to slightly bullish outlook. Short-term investors may consider taking advantage of the volatility and potential trading opportunities within the current price range.

Long-Term Investor

The 200-day SMA is providing a strong long-term support level, indicating a positive long-term trend for the stock. The company’s fundamentals and long-term growth prospects should be carefully evaluated to determine if it is a suitable investment for a long-term investor. Long-term investors may consider the stock as a potential investment, but should also monitor the company’s performance and any changes in the long-term trend.

Overall, the technical indicators suggest a mixed outlook, with potential trading opportunities in the short-term and a relatively positive long-term trend. Investors should carefully evaluate the company’s fundamentals and their own investment objectives before making any decisions.

Back to Table of Contents

Chart of Valuation History

"Chart of Valuation History"

Back to Table of Contents

Financial Statements Annual

Financial Statements Annual 2024 Q2

Goodwill Impairment

The company recognized a $26.1 million goodwill impairment charge in its transplant software reporting unit, primarily due to reduced revenue expectations. However, none of the company’s other reporting units were considered at risk of significant goodwill impairment as of December 31, 2023.

Tax Matters

The company’s effective tax rate was 18.7% in 2023, down from 20.5% in 2022, primarily due to the impact of non-controlling interests attributable to non-tax paying entities. The company has federal, state, and international net operating loss carryforwards that could provide future tax benefits.

Debt and Liquidity

The company refinanced its senior secured credit facilities in 2023, extending maturities and transitioning the interest rate benchmark from LIBOR to SOFR. As of December 31, 2023, the company had $1.5 billion available under its revolving credit facility and $464.6 million in cash and cash equivalents, providing ample liquidity.

Acquisitions and Divestitures

The company continued to make strategic acquisitions in 2023, spending $46.2 million on dialysis and other businesses. The pro forma financial information suggests these acquisitions had a modest positive impact on the company’s results.


The company is subject to various governmental investigations and legal proceedings, including a $40 million reserve related to an investigation by the U.S. Attorney’s Office in Colorado. While the ultimate outcomes of these matters are uncertain, they represent potential risks that a long-term investor should monitor.

Segment Performance

The company’s core U.S. dialysis segment remained the primary driver of profitability, generating $1.77 billion in operating margin. The other ancillary services segment reported a modest operating margin of $8.7 million.

Overall, the financial statements suggest the company maintains a strong market position in dialysis services, with a focus on managing costs, executing strategic acquisitions, and navigating the regulatory environment. A long-term investor should closely monitor the company’s ability to sustain its dialysis segment profitability, successfully integrate acquisitions, and resolve any outstanding legal and regulatory matters.

Financial Statements Annual 2023 Q2

Deferred Tax Assets and Valuation Allowance

The company has net deferred tax assets, but a valuation allowance is recorded to account for the unrealizable balances. The net increase of $6,159 in the valuation allowance is primarily due to newly created net operating loss carryforwards in state and foreign jurisdictions that the company does not anticipate being able to utilize. The company recognized a true-up in 2021 to increase net deferred tax assets by $46,692, which resulted in a $16,044 charge to income tax expense.

Unrecognized Tax Benefits

The company’s total liability for unrecognized tax benefits that do not meet the “more-likely-than-not” threshold is $63,985 as of December 31, 2022. $45,825 of the unrecognized tax benefits would impact the company’s effective tax rate if recognized. The company is under examination by various tax authorities, including the IRS for 2016 and 2017.

Long-Term Debt

The company’s total debt principal outstanding as of December 31, 2022 was $8,968,519. The weighted average effective interest rate on all debt, including the effect of interest rate caps and amortization of debt discount, was 3.96% for the year ended December 31, 2022. As of December 31, 2022, the company’s interest rates were fixed on approximately 51.3% of its total debt.


The company leases substantially all of its U.S. dialysis facilities, with the majority under non-cancellable operating leases ranging from 5 to 15 years. The company’s total future minimum lease payments under non-cancellable leases as of December 31, 2022 were $3,354,867 for operating leases and $331,982 for finance leases.

Acquisitions and Divestitures

The company acquired dialysis businesses and other businesses, including a transplant software company, for a total of $76,645 in 2022. The company divested its prior vascular access business, RMS Lifeline Inc., in May 2020 and recognized a loss on sale of approximately $16,252.

Overall, the key insights relate to the company’s tax position, debt structure, leasing activities, and acquisition and divestiture activities, which provide important context for understanding the company’s financial position and performance.

Financial Statements Annual 2022 Q2

Income Statement

The company’s revenue was $11.62 billion in 2021, up from $11.55 billion in 2020. The gross profit margin increased to 31.4% in 2021, up from 30.1% in 2020. Operating income grew to $1.80 billion in 2021, up from $1.69 billion in 2020. Net income increased to $978 million in 2021, up from $774 million in 2020. Earnings per share (diluted) were $8.9 in 2021, up from $6.51 in 2020.

Balance Sheet

As of December 31, 2021, the company’s total assets were $17.12 billion, up from $16.99 billion as of December 31, 2020. Total liabilities were $14.75 billion as of December 31, 2021, up from $14.62 billion as of December 31, 2020. Total stockholders’ equity increased to $755.5 million as of December 31, 2021, up from $540.3 million as of December 31, 2020. Net debt (total debt less cash and short-term investments) was $11.51 billion as of December 31, 2021, up from $11.48 billion as of December 31, 2020.

Cash Flows

Net cash provided by operating activities was $1.93 billion in 2021, up from $1.89 billion in 2020. Capital expenditures were $641 million in 2021, down from $674 million in 2020. Free cash flow (operating cash flow less capital expenditures) was $1.29 billion in 2021, up from $1.22 billion in 2020.

Other Highlights

The company completed 36 acquisitions in 2021, adding $173 million in goodwill. It also repurchased $1.55 billion of common stock in 2021. As of December 31, 2021, the company maintained a strong liquidity position with $554.9 million in cash and $1 billion in undrawn revolving credit facility.

Overall, the financial statements show that the company had a strong performance in 2021, with improvements in revenue, profitability, and cash flow compared to 2020. The company continues to invest in growth through acquisitions and return capital to shareholders through share repurchases, while maintaining a solid balance sheet and liquidity position.

Back to Table of Contents

Financial Statements Quarterly

Financial Statements Quarterly 2024 Q2

Revenue and Earnings

Total consolidated revenues were $3,070.6 million in Q1 2024, a 2.4% decrease from Q4 2023 but a 6.9% increase from Q1 2023. Operating income was $483.8 million in Q1 2024, a 24.1% increase from Q4 2023 and a 55.1% increase from Q1 2023. Adjusted operating income was $463.0 million in Q1 2024, a 16.1% increase from Q4 2023 and a 31.5% increase from Q1 2023.

Segment Performance

The US Dialysis segment revenue decreased 1.9% from Q4 2023 but increased 5.5% from Q1 2023. Operating income increased 18.5% from Q4 2023 and 45.7% from Q1 2023. The Other Ancillary Services segment revenue decreased 5.3% from Q4 2023 but increased 20.4% from Q1 2023. Operating income increased significantly from both prior periods.

Cash Flows and Liquidity

Net cash provided by operating activities decreased to $135.0 million in Q1 2024 from $463.0 million in Q1 2023, primarily due to the impact of the Change Healthcare (CHC) outage on the company’s ability to submit claims and collect payments. Free cash flow was $327.8 million in Q1 2024, compared to $265.0 million in Q1 2023. As of March 31, 2024, the company had $735 million available and $765 million drawn on its $1.5 billion revolving credit facility.

Other Highlights

The company recognized a $35.1 million gain on changes in ownership interest during Q1 2024. The company repurchased 2.1 million shares of common stock for $240.1 million during Q1 2024. The company plans to enter into a fourth amendment to its existing credit agreement to extend the maturity date of its senior secured term loan B1 facility.

Overall, the company demonstrated improved financial performance in Q1 2024 compared to both the prior quarter and the prior year period, despite the impact of the CHC outage on its cash flows. The company continues to focus on cost savings initiatives and strategic investments to drive future growth.

Financial Statements Quarterly 2024 Q1

Revenue growth

Total consolidated revenues increased 4.0% in Q3 2023 compared to Q2 2023, and 3.5% year-to-date in 2023 compared to the same period in 2022. The increase was driven by growth in the US dialysis and other ancillary services segments.


Operating income increased 22.5% in Q3 2023 compared to Q2 2023, and 12.0% year-to-date in 2023 compared to the same period in 2022. Adjusted operating income, which excludes certain charges, increased 21.5% in Q3 2023 compared to Q2 2023, and 15.4% year-to-date in 2023 compared to the same period in 2022.

Cost management

The company continued to implement cost savings initiatives, including increased use of third-party service providers and clinic optimization efforts. However, the company also incurred elevated costs related to center closures, severance, and increased labor and supply chain expenses.

Liquidity and cash flow

Net cash provided by operating activities increased 28.9% year-to-date in 2023 compared to the same period in 2022. Free cash flow increased 31.9% year-to-date in 2023 compared to the same period in 2022. The company refinanced its Term Loan A and revolving credit facility, adding $1.25 billion in new Term Loan A1 financing.

Segment performance

The US dialysis segment saw improved revenue per treatment and profitability, though it was impacted by elevated center closure and severance costs. The ancillary services segments, including integrated kidney care and international operations, showed mixed performance with some revenue and profitability growth.

Overall, the company demonstrated improved financial performance in Q3 2023 and year-to-date 2023 compared to the prior year, though it continues to face cost pressures from inflation, labor market conditions, and strategic initiatives. The company’s liquidity position remains strong, supported by growing cash flows.

Financial Statements Quarterly 2023 Q4

Revenue Growth

Total consolidated revenues increased 4.4% in Q2 2023 compared to Q1 2023, driven by a 4.6% increase in US dialysis revenues and a 2.8% increase in ancillary services revenues. For the first half of 2023, total consolidated revenues increased 2.2% compared to the first half of 2022, with US dialysis revenues up 2.0% and ancillary services revenues up 4.9%.

Volume and Utilization

US dialysis treatments increased 1.6% in Q2 2023 compared to Q1 2023, driven by one additional treatment day and increased average treatments per day. For the first half of 2023, US dialysis treatments decreased 0.2% compared to the first half of 2022, primarily due to decreased average treatments per day and fewer patients.


US dialysis operating income increased 27.7% in Q2 2023 compared to Q1 2023, driven by higher revenues and lower costs. For the first half of 2023, US dialysis operating income decreased 6.5% compared to the first half of 2022, primarily due to higher compensation expenses, other operating costs, and center closure charges. Ancillary services operating income decreased 12.0% in Q2 2023 compared to Q1 2023, but increased 12.2% for the first half of 2023 compared to the first half of 2022.

Liquidity and Capital

Net cash provided by operating activities increased 79.0% in the first half of 2023 compared to the first half of 2022, driven by improved cash collections and working capital. Free cash flow increased 116.9% in the first half of 2023 compared to the first half of 2022. The company refinanced its prior Term Loan A and revolving credit facility, obtaining a new $1.25 billion Term Loan A1 and $1.5 billion revolving credit facility.

Overall, the financial statements show improving revenue and profitability trends in the US dialysis business, though the company continues to face cost pressures. The company’s liquidity and capital position remain strong, with the recent debt refinancing providing additional financial flexibility.

Financial Statements Quarterly 2023 Q3

Revenue and Treatment Volume

Total consolidated revenues were $2.87 billion in Q1 2023, up 2.0% from Q1 2022. US dialysis patient service revenues increased 1.4% year-over-year, driven by a 0.1% increase in dialysis treatments and a 1.3% increase in average patient service revenue per treatment. The increase in treatments was due to higher patient census, partially offset by fewer treatment days.


US dialysis operating income was $361 million in Q1 2023, down 11.1% from Q1 2022, primarily due to increases in compensation expenses, travel costs, and other direct operating expenses. Adjusted US dialysis operating income was $400 million, down 2.7% year-over-year. Ancillary services operating income was $25 million, down 21.9% from Q1 2022, mainly due to a decrease in shared savings in the IKC business. Adjusted ancillary services operating income was $24 million, down 25.0% year-over-year.


Patient care costs per treatment in the US dialysis segment increased 1.9% year-over-year, driven by higher compensation expenses and other direct operating costs. General and administrative expenses in the US dialysis segment increased 19.4% year-over-year, primarily due to higher compensation expenses, including severance costs, and increased travel and management meeting costs.

Cash Flows and Liquidity

Net cash provided by operating activities was $463 million in Q1 2023, up 43.8% from Q1 2022, primarily due to a decrease in days sales outstanding (DSO). Free cash flow was $265 million in Q1 2023, up 80.3% year-over-year. As of March 31, 2023, the company had $317 million in cash and cash equivalents and $1.0 billion available under its revolving credit facility.

Subsequent Events

The company amended its senior secured credit facilities, including refinancing its Term Loan A and revolving line of credit. The company entered into several forward interest rate cap agreements to hedge its exposure to variable interest rate changes.

Overall, the financial statements show that DaVita faced some headwinds in its US dialysis and ancillary services businesses, with higher expenses offsetting revenue growth. However, the company’s strong cash flow generation and liquidity position provide flexibility to navigate the current operating environment.

Back to Table of Contents

Earnings Call Analysis

Earnings Call Analysis 2024 Q1

Resilience and Strong Financial Results

DaVita has demonstrated resilience in its business despite external challenges in recent years. The company was able to deliver strong financial results in 2023 by investing in its people, processes, and systems.

Integrated Kidney Care (IKC) Progress

The company’s integrated kidney care (IKC) business continues to show progress, with growth in total medical expense and covered lives. While still operating at a loss, DaVita expects the IKC business to reach breakeven or better performance by 2026.

Guidance for 2024

DaVita is guiding for 10% growth in adjusted operating income and 9% growth in adjusted EPS for 2024, demonstrating the underlying strength and predictability of the core dialysis business.

Revenue Cycle Management Improvements

The company has made improvements in its revenue cycle management, which has resulted in higher revenue per treatment. This, combined with cost savings initiatives, is expected to drive the 2024 financial guidance.

Cautious Approach to GLP-1 Drugs

DaVita remains cautious on the potential impact of GLP-1 drugs, maintaining its view of a net neutral impact on dialysis volume growth as adoption ramps up over the next decade.

Center Footprint Optimization

The company is focused on optimizing its center footprint, with plans to close or merge around 50 centers in 2024, which should provide further cost savings.

Analysts’ questions suggest close attention to trends in Medicare Advantage and commercial payer dynamics, as well as the potential impact of regulatory changes like AB 290 in California.

Overall, DaVita appears to be in a stronger position operationally and financially, with a focus on driving efficiencies and growth in its core dialysis business while continuing to invest in its IKC initiatives.

Earnings Call Analysis 2023 Q4

DaVita’s Earnings Call Insights for Long-Term Investors

DaVita is focused on near-term operating discipline while continuing to invest for future growth. They are creating a differentiated experience for employees and delivering high-quality care for patients.

On the impact of GLP-1 drugs, DaVita has done extensive modeling and analysis, incorporating input from external experts. Their conservative assumptions are:

  • 30% of the CKD population will use GLP-1 drugs
  • These drugs will slow CKD progression by 25% on average
  • This is expected to have a negligible impact (0.5% annual growth headwind) on DaVita’s long-term dialysis volume and operating income growth targets

DaVita is revising its 2023 guidance upwards, expecting continued strong performance. They expect 2024 to be a year of positive volume and operating income growth.

DaVita is comfortable resuming share repurchases, using a combination of excess cash flow and capacity in its revolving credit facility.

The company remains focused on delivering the best care today while also investing in capabilities and care models for the future.

The key takeaway is that DaVita has done thorough analysis on the potential impact of GLP-1 drugs and believes it will not materially affect their long-term growth trajectory, despite market concerns. The company continues to execute well operationally and is taking a balanced approach to capital allocation.

Earnings Call Analysis 2023 Q3

Operational Improvements

DaVita has been focused on innovation and continuous improvement to provide high-quality care for patients. This includes the rollout of their new clinical IT system “Center Without Walls” which aims to improve data sharing and enable future AI capabilities.

DaVita is seeing improvements in census and treatments per day, indicating a recovery in volume. If these trends continue, they expect to deliver volume growth in 2024.

Revenue Per Treatment (RPT)

RPT was strong, driven by seasonal factors, rate increases, and improvements in revenue cycle management. DaVita expects 2.5-3% year-over-year RPT growth.

Cost Management

While base wage increases remain high, DaVita has reduced other expenses like contract labor and pharmaceuticals. However, elevated training costs remain a headwind.

Reimbursement Challenges

DaVita is disappointed with the proposed 2024 ESRD payment system update from CMS, as it falls short of expected cost inflation. The company will continue advocating for an adjustment mechanism.

Guidance Increase

DaVita has increased its full-year 2023 guidance for adjusted operating income and EPS, citing improvements in RPT and volume trends.

Capital Allocation

DaVita is focused on capital-efficient growth, maintaining a target leverage ratio of 3-3.5x EBITDA, and returning excess cash flow to investors through share buybacks.

Overall, the key insights highlight DaVita’s operational improvements, volume recovery, and cost management efforts, while also noting the reimbursement challenges and the company’s capital allocation priorities.

Earnings Call Analysis 2023 Q2

Labor management is a critical focus area

DaVita has made progress in reducing contract labor costs and improving permanent staffing levels, which has helped margins. However, training costs remain elevated due to high turnover, which they expect to improve in the back half of the year.

Q1 treatments per day were up 1% sequentially, driven by higher admissions and lower mortality. While they still expect a year-over-year decline, the Q1 results put them on track to potentially finish the year in the top half of their volume forecast range.

Integrated Kidney Care (IKC) program is showing promising results

Over 50% of IKC patients achieve an “optimal start” which reduces costly hospitalizations. IKC also shows lower hospitalization rates compared to the overall patient population. However, the IKC business is still in investment mode.

Cost savings initiatives are on track

DaVita expects $125-$175 million in year-over-year savings, primarily from pharmaceutical cost reductions and facility consolidations. This is a key driver of the improved 2023 outlook.

Cautious optimism, but uncertainties remain

While Q1 results were strong, DaVita remains cautious about the broader macro environment and the continuation of current trends. Excess mortality and labor market pressures are still factors to monitor.

Overall, the key message is that DaVita is making operational improvements and executing on its strategic initiatives, which is translating to better than expected financial performance. However, the long-term investor should continue to watch for any changes in the labor market, treatment volume trends, and the progress of the IKC program.

Earnings Call Analysis 2023 Q1

Labor costs and staffing challenges

Labor costs and staffing challenges remain a key swing factor in DaVita’s performance, though they are seeing some improvement. Contract labor costs are expected to remain elevated compared to pre-COVID levels in 2023.

Patient volumes

Patient volumes are still under pressure, with new patient admissions and missed treatments continuing to be a headwind. DaVita is guiding for a 0-3% decline in treatments in 2023, though the lack of a major COVID surge so far this winter has improved the outlook.

Strategic priorities

DaVita is focused on strategic priorities like digital modernization, policy advocacy, home dialysis adoption, and growing its Integrated Kidney Care business. These initiatives are important for the company’s long-term competitiveness.

Cost management

The company is maintaining a disciplined approach to cost management, including transitioning to a new anemia therapy and consolidating its facility footprint. This is important given the lack of pace in Medicare rate increases.

Integrated Kidney Care segment

Analysts probed for more details on patient growth trends and the outlook for DaVita’s Integrated Kidney Care segment, which is a key growth driver. The company provided some color but maintained a cautious tone given the uncertainties.

Overall, the call highlights DaVita’s efforts to navigate near-term challenges while investing in its long-term capabilities. Investors should watch for continued progress on labor, volumes, and strategic initiatives as indicators of the company’s trajectory.

Earnings Call Analysis 2022 Q4

Volume and Labor Challenges

Volume and labor challenges are the biggest uncertainties impacting DaVita’s results. The company is now assuming these headwinds will persist longer than previously expected.

Patient Census and Metrics

Patient census growth, net treatment rates, and excess mortality remain depressed compared to pre-COVID levels. The company does not have clear visibility on when these metrics will rebound.

Labor Costs

Labor costs, including wage rates, contract labor, and training expenses, have been elevated and are expected to remain so in the near-term. The company is implementing cost-saving initiatives to offset these pressures.

Transition and Optimization

The company is transitioning to a new anemia management contract (Mircera) in 2023, which is expected to provide meaningful savings. They are also optimizing their clinic footprint and reducing G&A expenses.

Guidance and Forecasting

The company has taken a more conservative approach in its guidance, assuming the current challenging environment persists rather than anticipating a rebound. This represents a philosophical shift in their forecasting approach.

Debt Reduction and Share Repurchases

The company plans to focus more on debt reduction to get leverage back to its target range, rather than aggressive share repurchases going forward.

Overall, the key message is that DaVita is facing significant near-term headwinds from COVID-related volume and labor pressures, and the company is taking a more cautious stance in its outlook until there is clearer visibility on these industry dynamics.

Earnings Call Analysis 2022 Q3

Health Equity

DaVita has achieved unparalleled equity in access to care, information, and clinical outcomes across different patient populations. They are working to improve access to transplants and home dialysis.

Regulatory Challenges

The Supreme Court’s Marietta Memorial Hospital ruling created a loophole that could allow plans to circumvent protections for dialysis patients. DaVita is working with the community on legislative and regulatory initiatives to close this loophole.

Financial Performance

  • Q2 results benefited from one-time items like a gain on property sale and earlier-than-expected recognition of shared savings revenue in the Integrated Kidney Care (IKC) business. These are not expected to recur in the second half.
  • Labor costs remain a challenge, with higher contracted labor utilization and wage increases.
  • IKC business performance is expected to be better than initially expected for 2022, but the improvement in 2023 is now expected to be lower than previously anticipated.

2023 Outlook

  • The range for operating income growth in 2023 has been lowered to $200-$300 million, down from $250-$400 million previously.
  • This is primarily due to continued uncertainty around treatment volume growth and wage pressure, partially offset by higher revenue per treatment growth.
  • The company still expects a meaningful rebound in 2023 but with more muted improvement than previously communicated.

Analyst Questions

  • The company does not expect material impact from the Marietta ruling on payer mix in 2023.
  • Wage pressure is expected to remain elevated in 2023, with increases somewhere between 3-6% year-over-year.
  • The company is exploring partnerships and initiatives to drive efficiency and offset cost headwinds.

Overall, the key insights highlight the company’s focus on health equity, the regulatory challenges it faces, the near-term financial pressures, and the more cautious outlook for 2023 compared to previous expectations. Long-term investors should closely monitor the company’s ability to navigate these dynamics.

Earnings Call Analysis 2022 Q2

Cost Pressures

DaVita is facing significant cost pressures, particularly from higher wage rates and labor shortages. They expect these cost pressures to continue in 2023, though they are working on various cost-saving initiatives to help offset the impact.

COVID-19 Impact

The company has seen significant impacts from COVID-19, including excess patient mortality and treatment volume declines. While the Omicron variant has had a lower mortality rate, the sheer volume of cases still resulted in substantial excess mortality. The company remains cautious about future COVID surges and their potential impact.

Integrated Kidney Care (IKC) Business

DaVita sees significant potential in its IKC business, with strong growth in delegated patient volumes, new payer partnerships, and nephrologist engagement. The company is confident in its clinical model and expects the IKC business to contribute to its long-term growth.

Rebound in 2023

The company expects a rebound in operating income in 2023, driven by growth in the core business, a reversal of some COVID-19 headwinds, and progress in the IKC business. However, the magnitude of the rebound will depend on the company’s ability to manage ongoing cost pressures and the continued impact of COVID-19.

Payer Negotiations

DaVita acknowledges the challenges in negotiating higher rates with commercial payers, given the payers’ market power. The company expects relatively low net rate updates in the near-term, with most of its contracts being multi-year.

Overall, the key insights highlight the company’s efforts to navigate the current challenging environment, while investing in its long-term growth opportunities. Investors should closely monitor the company’s ability to manage cost pressures, the ongoing impact of COVID-19, and the progress of the IKC business.

Earnings Call Analysis 2022 Q1

COVID-19 Impact

COVID-19 continues to have a significant impact on DaVita’s business, with spikes in infections and mortality rates. The company is unable to reliably forecast the future impact of COVID-19.

Labor Market Challenges

Labor market challenges remain a major headwind, with DaVita needing to provide significant wage increases to attract and retain talent. This is putting pressure on the company’s cost structure.

Supply Chain Issues

Supply chain issues, particularly related to dialysate shortages, are an industry-wide challenge that DaVita is working to navigate.

Integrated Kidney Care (IKC) Business

DaVita is investing heavily in its Integrated Kidney Care (IKC) business, which is expected to have a $50 million incremental operating loss in 2022. The long-term potential of this business is emphasized, but near-term profitability is unclear.

Guidance Update

The company’s guidance for 2022 was lowered by $35 million compared to previous expectations, primarily due to higher labor costs and COVID-19 impacts, which offset tailwinds from Medicare rate updates and sequestration relief.

Medicare Advantage Focus

DaVita remains focused on growing its Medicare Advantage patient population, which provides an offset to some of the headwinds the company is facing.

Long-Term Outlook

The company’s long-term outlook for 3-7% annual adjusted operating income growth and 8-14% annual adjusted EPS growth remains unchanged, but the near-term path to achieving this is more uncertain due to the dynamic operating environment.

Overall, the call highlights the significant near-term challenges DaVita is navigating, while emphasizing the company’s long-term strategic priorities and confidence in its ability to deliver value over time. Investors should closely monitor the company’s ability to manage labor and COVID-19 costs, as well as the progress of the IKC business.

Earnings Call Analysis 2021 Q4

DaVita’s Core Dialysis Business Remains Strong

DaVita’s core dialysis business remains strong despite the challenging operating environment. The company has been able to manage costs and deliver solid financial results.

COVID-19 Pandemic Continues to Impact DaVita

The COVID-19 pandemic continues to impact DaVita, with increased mortality and higher costs. The company expects the financial impact of COVID to be worse than previously anticipated in 2021.

Progress in Home Dialysis

DaVita is making progress in home dialysis, with over 15% of patients now receiving home dialysis. The company has invested in infrastructure and technology to support this growing part of the business.

Integrated Kidney Care (IKC) Business Expected to Double in Size

DaVita’s Integrated Kidney Care (IKC) business is expected to double in size in 2022, driven primarily by participation in the federal government’s new CKCC program. However, this business is currently generating losses that are expected to continue into 2023.

2022 as a Transition Year

2022 is expected to be a transition year, with several temporary headwinds impacting operating income, including increased labor costs, the California ballot initiative, and higher depreciation. These headwinds are expected to reverse in 2023, allowing for a return to stronger operating income growth.

Long-term Outlook Remains Positive

The long-term outlook for DaVita remains positive, with the company anticipating a low-to-mid single digit CAGR in operating income from 2021 to 2023, assuming the resolution of the temporary headwinds.

Overall, the call suggests DaVita is navigating the current challenges well, while investing in growth areas like home dialysis and integrated care. However, investors should be cautious about the near-term headwinds and the company’s ability to execute on its long-term strategy.

Earnings Call Analysis 2021 Q3

Integrated Kidney Care (IKC) is a major strategic focus for DaVita

IKC represents around $2 billion in annual medical costs under management currently, which DaVita expects to double in 2022. DaVita believes it is well-positioned to lead in value-based kidney care due to its partnerships with nephrologists, patient interactions, broad care platform, and data/analytics. However, the IKC business will incur significant operating losses in 2021 ($120 million) and 2022 ($50 million incremental) as DaVita invests in scaling up this business. Over a 5+ year horizon, DaVita believes the IKC business could become a significant driver of operating income growth, potentially reaching low single-digit margins on the $12 billion in total healthcare spend it manages.

Core dialysis business remains strong

Dialysis treatment volumes are recovering, though still impacted by COVID-19 excess mortality. DaVita expects to return to pre-pandemic treatment growth levels, with potential tailwinds from lower-than-normal mortality rates. Patient care costs and G&A expenses per treatment have been well-managed.

Potential headwinds

Continued COVID-19 impact, especially from the Delta variant, could result in higher excess mortality and costs in the second half of 2021. Union activity and new IT platform depreciation could pressure operating income growth in 2022.

Disclosure and transparency

DaVita plans to provide more disclosure on the IKC business, including revenue and operating income, as it scales up. Investors should focus on the U.S. strategic initiatives segment as a proxy for the IKC P&L.

Overall, the key is DaVita’s strategic shift towards value-based kidney care, which represents a significant long-term opportunity but also near-term investment and risk. Investors should monitor the company’s execution and financial performance in this transition.

Back to Table of Contents

The information provided on this blog is for informational purposes only and should not be considered as financial advice. You should consult with a qualified financial professional before making any investment decisions. Past performance is not indicative of future results. Investing involves risk, including the potential loss of principal.